Sporadic Angiomyolipomas (AMLs) Growth Kinetics While on Everolimus

Inclusion Criteria: * Must have a diagnosis of renal AML \> 3 cm confirmed on pre-enrollment Dynamic Contrast Enhanced MRI (DCE-MRI) * Must not have received any prior treatment for AML * Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1 * Absolute neutrophil count \>= 1,500/ microliter (mcL) * Hemoglobin \>=10 g/dL * Platelets \>= 100,000/ mcL * international normalized ratio (INR) \<= 1.2 X Upper limit Normal (ULN) * activated partial thromboplastin time (aPTT) \<= 1.2 X ULN * aspartate aminotransferase (AST) / alanine transaminase (ALT) \<= 2.5 X ULN * Total bilirubin \<= 2.0mg/dL * Renal Function epidermal growth factor receptor (eGFR) \>= 30 mL/min via calculated creatinine clearance * Fasting serum cholesterol \<= 300 mg/dL OR \<= 7.75 mmol/L AND fasting triglycerides \<= 2.5x ULN. Exclusion Criteria: * History of tuberous sclerosis, LAM or any active malignancy * Treatment with any other investigational agents for any other disease * Clinically significant gastrointestinal abnormalities that may increase the risk for gastrointestinal bleeding or affect absorption of investigational product * Active diarrhea of any grade. * History of human immunodeficiency virus (HIV) infection, hepatitis B or C (screening for all three is mandatory prior to study); prior hepatitis C infection * Presence of any active or ongoing infection. * Any known uncontrolled underlying pulmonary disease by history, physical exam or if applicable pulmonary function test (PFTs)…